Medeze Group posts in excess of B500m revenue in 2021
Dr Veerapol says Medeze is committed to delivering new options that enable people to live a longer and better life.
Leading stem cell firm Medeze Group reported more than 500 million baht in revenue in 2021, a 25% increase from the previous year.
The company, which focuses on body deterioration rehabilitation, said it was able to increase the number of clients to an average of 3-4 people per family in response to the trend of health awareness following the pandemic.
Dr Veerapol Khemarangsan, executive director and chairman of Medeze Group’s board, said the company is committed to delivering new options that enable people to live longer, better lives.
“Net profit totalled 123 million baht, growing more than 20% from the same period last year,” he said.
“Our significant income boost is attributed to the total amount of stem cell deposits from adipose tissue, which increased the number of customers more than threefold on average, or 3-4 people per family, compared with only one client per family. The larger client base allowed greater collection of stem cells from newborn umbilical cord tissue.”
Dr Veerapol said 28% of this income came from the natural killer (NK) cell analysis business of Medeze NK Co, totalling more than 140 million baht.
The majority of revenue is generated by the vast volume of stem cell preservation and culture in Thailand and other Asean nations, including Vietnam, Myanmar, Singapore, Cambodia and Indonesia.
Taiwan is another growing market, he said.
As for the 2022 business strategy, Medeze Group expects growth to increase by 100-200% this year.
The firm plans to increase its presence in Asean, as well as China, Taiwan and the Middle East.
Dr Veerapol said the investment budget for R&D will be expanded, while the company wants to establish its own laboratories in various countries across the region during the next six years.
The group plans to commence building its own lab facilities in Dubai in 2023; in Shenzhen, China in 2024; in Indonesia in 2025; in Vietnam in 2026; and in Taiwan in 2027.
“Many countries rely on us to provide high-quality services that adhere to international standards and medical ethics. As a result, the use of our stem cells to support future treatment is a testament to our effectiveness and commitment to customer safety,” he said.
“All of these factors contribute to Medeze Group’s strong positioning as the first and only brand in Asean to offer longevity services with state-of-the-art bio-longevity technology.”